Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Sb. x. x., č. 46/2008 Xx. x. x. a x. 47/2012 Sb. x. x. x Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx zahraničních věcí xxxxxxx, xx dne 16. xxxxxxxxx 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Přílohy X - Seznamu xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu ve xxxxxx.1)
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2012 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx X Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. ledna 2011 a xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx I x její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Mezinárodní xxxxxx proti dopingu xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX PROTI XXXXXXX XX XXXXXX
Příloha X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX A XXXXX DOPINGU XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. ledna 2012
Podle článku 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Zakázané xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek ze xxxxxx X1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 x M3.
XXXXX X METODY ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX) |
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx aktuálně xxxxxxxxx xxx humánní xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. léčiva x preklinickém xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx léky), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX LÁTKY
Anabolické xxxxx xxxx xxxxxxxx.
1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); miboleron; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), testosteron x jejich metabolity x isomery, ale xx x xxxxxxxx xxxxx xx xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (androst-5-en-3,17-dion) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
androst-5-en-3α,17β-dioI | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:
Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" se xxxxxxxx x xxxxx, xxxxxx xxxx xxxx normálně xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx může xxxx xxxxxxxxxx přirozeně. |
X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx a xxxxxx uvolňující faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. erytropoetin (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) u mužů;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx xxxxxxx faktory (XXX), růstový xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), stejně xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx zásobení, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx vláken;
x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
S3. XXXX2- XXXXXXXX
Všichni xxxx-2 xxxxxxxx (včetně xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx pokud xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x moči x koncentraci xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x moči v xxxxxxxxxxx xxxxx než 30 xx/xx xxxxxx xxxxxxxxxx za zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx považována xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx abnormální výsledek xxx xxxxxxxx užíváním xxxxxxxxxxxx inhalační xxxxx xxxxx xxx xxxx xxxxxxx maximum.
S4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Aminoglutethimid, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, formestan, xxxxxxxx, xxxxxxxxxxx, ale xx s xxxxxxxx xxxxx xx ně.
2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (SERM), xxxxxxxxxx:
Raloxifen, tamoxifen, xxxxxxxxx, xxx ne x xxxxxxxx pouze xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x xxxxxxxx pouze xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx ne x xxxxxxxx pouze xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx aktivovaný peroxizomovými xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. GW 1516) x Xxxxxxxx proteinkinasové xxx aktivované AMP x součinnosti x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
S5. DIURETIKA X XXXXXXX MASKOVACÍ XXXXX
Maskovací látky xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. glycerol, nitrožilní xxxxxx albuminu, dextranu, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx účinky. Lokální xxxxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx není xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které nejsou xxxxxxxx).
Xxx použití (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) jakéhokoliv xxxxxxxx látky xx xxxxxxxxxx prahovým xxxxxxx (xx. formoterol, xxxxxxxxxx, xxxxxx, katin, efedrin, xxxxxxxxxxxx x pseudoefedrin) xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx látkou je xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x té, xxxxx xxx xxxx udělena xx diuretikum xxxx xxxxx xxxxxxxxx látku.
XXXXXXXX XXXXXX
M1. XXXXXXXXX PŘENOSU XXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxx xxxxxx, xxxxxx použití autologní, xxxxxxxxx nebo heterologní xxxx xxxx červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky kyslíku, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx xx hemoglobinu, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), perfluorochemikálie x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx pouze xx xx. Dodávání xxxxxxx xxxxxxxx není.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx pokus x xxxxxx, za účelem xxxxxxx integritu x xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx ne x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx 50 xx za 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Postupný xxxxx, xxxxxxxxxx a xxxxxxxxx jakéhokoliv xxxxxxxx xxxx xxxx xx xxxxxxxxx xxxxxxx xx xxxxxxxx.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx ke zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:
1. Xxxxxxxx nukleových kyselin xxxx jejich xxxxxxxx;
2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
LÁTKY X XXXXXX XXXXXXXX XXX XXXXXXX |
Xxxxx xxxxxxxxx XX xx S5 a X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Soutěži xxxxxxxx x následující xxxxxxx:
XXXXXXXX LÁTKY
S6. XXXXXXXXXXX
Xxxxxxx stimulancia (xxxxxx xxxx jejich xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx, s xxxxxxxx xxxxxxxx imidazoiu x případě xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2012*.
Stimulancia xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, amfepramon, xxxxxxxxxxx, xxxxxxxxx, amifenazol, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, dimethylamfetamin, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metamfetamin (x-), methylendioxyamfetamin, methylendioxymetamfetamin, xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx není xxxxxxxx xxxxxxx v xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxxx stimulancia (příklady):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, methylhexanamin (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, strychnin, xxxxxxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.
* Následující xxxxx xxxxxxxx xx Monitorovacího xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol, synefrin) xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.
** Xxxxxxx podání xxxxxxxxxx (xxxx. nosní, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx s xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Efedrin x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx xx zakázán, xxxxx xxxx koncentrace x xxxx je xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, metadon, morfin, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
S8. KANABINOIDY
Xxxxxxxx (xxxx. xxxxx, xxxxxx a marihuana) xxxx xxxxxxxxxx xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) a kanabimimetika (xxxx. "Spice" /obsahující XXX018, XXX073/ a XX-210) jsou zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx aplikací jsou xxxxxxxx.
LÁTKY XXXXXXXX V XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Alkohol (xxxxxx) xx zakázaný xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce xx bude provádět xxxxxxxx zkouškou x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro xxxxxxxx xxxxxxxxxxx pravidla (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (FIM)
∙ Xxxxx motorismus (UIM)
X2. BETA-BLOKÁTORY
Xxxxx xxxx jinak určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Při Soutěži x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxxxx (xxxxxxx discipliny) (XXXX)
∙ Xxxxx (XXX)
∙ Golf (XXX)
∙ Kuželky x xxxxxxx (XXX)
∙ Xxxxxxx sporty x xxxxxxxxxxxx (FAI)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x snowboard U-rampa x "xxx air"
∙ Petanque a xxxxxxx xxxxxx (XXXX)
∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (WDF)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx zahrnují následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, bisoprolol, xxxxxxx, celiprolol, esmolol, xxxxxxxxx, karvedilol, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, sotalol, timolol, xxx xx x xxxxxxxx xxxxx xx xx.
Informace
Xxxxxx xxxxxxx č. 97/2012 Xx. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx č. 97/2012 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x xxxxxxxxx xx 20.12.2013.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.